MIRA Pharmaceuticals, Inc. (MIRA)
NASDAQ: MIRA · Real-Time Price · USD
1.340
-0.070 (-4.96%)
Sep 12, 2024, 4:00 PM EDT - Market closed
MIRA Pharmaceuticals Employees
The last reported number of employees for MIRA Pharmaceuticals was 3.
Employees
3
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,261,429
Market Cap
19.81M
No historical employees data available.
Related Stocks
| Company Name | Employees |
|---|---|
| Renalytix | 102 |
| NKGen Biotech | 63 |
| HCW Biologics | 45 |
| Inspira Technologies Oxy B.H.N. | 42 |
| Brainstorm Cell Therapeutics | 29 |
| NeurAxis | 19 |
| NeuroSense Therapeutics | 18 |
| SeaStar Medical Holding | 12 |
MIRA News
- 1 day ago - MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Accesswire
- 17 days ago - MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study - Accesswire
- 24 days ago - MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End - Accesswire
- 4 weeks ago - MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor - Accesswire
- 7 weeks ago - MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action - Accesswire
- 7 weeks ago - S&P 500 Gains 1%; MIRA Pharmaceuticals Shares Spike Higher - Benzinga
- 7 weeks ago - MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance - Accesswire
- 2 months ago - Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC - Accesswire